Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia
Anaemia is a common consequence of chronic renal failure. Darbepoetin alfa is a unique erythropoietic protein that stimulates erythropoiesis by the same mechanism as endogenous erythropietin and conventional recombinant human erythropoietin (rHuEPO). Darbepoetin alfa has been shown to have a serum half-life 3-fold longer than that of rHuEPO, which allows dosing at extended intervals and less frequent injection.
The objective is to evaluate the efficacy and safety of darbepoetin alfa therapy given at an extended once monthly dosing interval in the treatment of renal anaemia in continuous ambulatory peritoneal dialysis.
Kidney Failure, Chronic
Peritoneal Dialysis, Continuous Ambulatory
Drug: Darbepoetin alfa
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Conversion From Once Weekly Recombinant Human Erythropoietin to Once Monthly Darbepoetin Alfa for the Treatment of Renal Anemia in Continuous Ambulatory Peritoneal Dialysis Patients|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00563446
|Princess Margaret Hospital|
|Hong Kong, China|
|Principal Investigator:||Samuel KS Fung, Dr||Division of Nephrology, Medicine & Geriatrics, Princess Margaret Hospital|